Navigation Links
Endomysial Antibody, IgA

ProductsEndomysial Antibody, IgA
Company ARUP Laboratories
Item Endomysial Antibody, IgA
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. ImmuGlo Anti-Endomysial Antibody (EMA) Test System
2. Tissue Transglutaminase Antibody, IgA with Reflex to Endomysial Antibody, IgA Titer by IFA
3. Adenovirus Antibody, IgG
4. Adenovirus Antibody, IgM
5. Anti-Cardiolipin Antibody, IgG
6. Anti-Cardiolipin Antibody, IgM
7. Anti-Centromere Antibody, IgG
8. Anti-dsDNA Antibody, IgG
9. Anti-GBM Antibody, IgA (IFA)
10. Anti-GBM Antibody, IgG (IFA)
11. Anti-GBM Antibody, IgG (ELISA)
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes.
...aspiration holes and additional electrode tip insu...recise dissection with decreased risk of collatera... design options allow the choice between retractab...designs. Optimize specific surgical demands safely...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Medicine Products:
(Date:12/3/2008)...n television viewers will get,a chance to learn a... when the,documentary "The Brain That Changes Its... network. Based on the best-selling book of the sa...ary traces the development of the,science of neur...products and,customers of Posit Science Corporati...
(Date:12/3/2008)...ion Agency,s process of generating risk assessment...posed by harmful chemicals found in the environmen...own by unprecedented challenges, and as a decision...between available scientific data and the informat... National Research Council. EPA,s risk assessment...
(Date:12/3/2008)...8 , , LOVELAND, Ohio, Dec. 3 /PRNewswire/ ...a non-profit 501(c)(3) organization, is pleased to... new Methods Evaluation ProcessTM (MEPTM) Accredit...st a complimentary Webinar to provide an overview ...rder to make transparent attributions between inte...
(Date:12/3/2008)... a MED3OOO company that,delivers EHR technology t...nics, recently entered into a 14-year Application ...Care Alliance to provide electronic medical record... The WVVA Healthcare Alliance is made up of 30 ... Alleghany Highlands of Virginia and the Greenbrie...
Breaking Medicine News(10 mins):Health News:Posit Science Featured in Canadian Documentary on the Brain 2Health News:EPA's risk assessment process bogged down by unprecedented challenges; 2Health News:EPA's risk assessment process bogged down by unprecedented challenges; 3Health News:EPA's risk assessment process bogged down by unprecedented challenges; 4Health News:Population Health Impact Institute Invites Organizations To Serve as Test Sites for Methods Evaluation Process(TM) (MEP(TM)) Accreditation Program: 2Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 2Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 3Health News:WVVA HealthCare Alliance Signs 14-Year ASP EHR Agreement 4
... Human Services (HHS) and its Centers for Disease ...Infant Immunization Week (NIIW) with events// Apri...the United States are expected to participate in N...ng the importance of timely infant and childhood v...
...parent failure by official bodies to halt the dist...ies have been incidents caused by E. coli contami...as well as pet food. Around 200 persons were aff...aminated with E.coli. A publicized incident was th...
...ences (AIIMS) has developed artificial testis, whi...r, underdeveloped genitals.// Doctors at the prem...ver 50 patients suffering from such problems, achi... "We are producing artificial testis and have trea...
...ed so high a priority in the minds of concerned he...here are moves to do away with regular school snac...are contributing to ungainly as well as dangerous ...the Institute of Medicine has been set up by the U...
Other Medicine News:Health News:National Infant Immunization Week Urges Parents to Vaccinate On Time 2Health News:U.S Officials Worried Over Failure In Preventing Food Contamination 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:Weight Issues In Children-Experts Take Stock 2
(Date:12/3/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI...ompany,s,manufacturing and control process descri...onovo can move forward with the development of Men...ashes. , "We have concluded three CMC discu...e Agency,s recommendations for further development...
(Date:12/2/2008)... -- IBT Laboratories, a leading clinical-diagnost...g in immunology and allergy assays, announced that...nse of patients whose immune systems may be compro...chemotherapy drugs, or because they are taking imm...ansplant. The company launched the two new assays,...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)...reated With ENB-0040 at Children,s Hospital, Healt... Dec. 1 Enobia Pharma, an emerging...vel therapeutics for serious bone disorders, today...inical program for hypophosphatasia was dosed. Eno...RT) with ENB-0040 for the treatment of this rare a...
Breaking Medicine Technology:Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 1Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 2Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 3ChanTest Launches Redesigned Web Site 5877 1ChanTest Launches Redesigned Web Site 5877 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 1Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 3Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 4Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 5LMXonline Offers Spanish Language Safety and Health Training Library 5873 1LMXonline Offers Spanish Language Safety and Health Training Library 5873 2
...unces Positive Top-Line Phase III Results for,Kepp...izures in,Paediatric Patients from One Month to Le...ril 20, 2007 - UCB today announced,positive top-li...zed, multi-centre, placebo-controlled study evalua...(levetiracetam) (20-50,mg/kg/day) as adjunctive th...
...dy Demonstrated the Clinical Potential of Peregrin...ere as Effective as,Avastin(R) in Animal Cancer Mo...irstCall/ --,Peregrine Pharmaceuticals, Inc. , a c... targeted monoclonal antibodies,for the treatment ...eported that data from multiple studies presented ...
Other Medicine Technology:UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7